Sputnik V denounced the Brazilian regulator for …

While Jair Bolsonaro insists on avoiding restrictions to control the pandemic in collapsed Brazil, the country’s health regulator, Anvisa, faces a libel lawsuit from none other than the vaccine makers Sputnik V, as confirmed by the Russian Fund for Direct Investments.

Three days ago, Anvisa denied importing the Russian vaccine, saying there are “uncertainties” about its safety and vaccine efficacy against the coronavirus. At the time, the Gamaleya Institute warned that there was a “political” context to the decision, in reference to the management of the pandemic led by Bolsonaro, a fierce opponent of the restrictions to fight against “fluzinha”, as the president called him sick. From the start of its administration, the ultra-right has also forged links with the United States, a country which has marked political differences with Moscow.

The Rdif now assures that the entity made these declarations “without having analyzed samples of the vaccine and without taking into account the official documents sent by the Gamaleya Institute on the absence of adenovirus “.

Consequently, for vaccine manufacturers, this is information disseminated knowing that “it was false and inaccurate.”

In a chain of messages on the social network, Sputnik V also points out that Anvisa admits the error, and quotes Gustavo Mendes, director of drugs and biologics of the entity who admitted: “We did not receive any samples of the vaccine to be tested. must be kept safe, we have not tested a replicated adenovirus. “

Anvisa on Monday rejected a request from several states in the country to import the vaccine, approved to date in 62 countries, including Argentina and 11 other countries in Latin America and the Caribbean, arguing that technical data is lacking to verify its safety. and its effectiveness.

From Russia, vaccine developers reacted instantly: “Anvisa’s delays in approving Sputnik V are unfortunately political in nature and have nothing to do with access to information or scientific aspects . “

In Brazil, Anvisa’s decision also sparked criticism, including that of the former Minister of Health under the government Dilma Rousseff and the current federal deputy Alexandre Padilh, who assured that the refusal of the body to regulation to approve the drug was tied to President Jair Bolsonaro “and his foreign. policy”.

In February, the prestigious medical journal The Lancet reported that the drug’s effectiveness was 91.6%, a figure that dispelled doubts about its reliability.

So far, countries like South Korea, Egypt, India, Mexico, Nepal, Kazakhstan and Uzbekistan have acquired the production rights.

Argentina will be the first Latin American country to produce the vaccine after an agreement with the Argentinian laboratory in Richmond.